YOLFTbeta
Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

0.5738USD+0.05 (+9.86%)

Price History

Full chart

Market Stats

Previous Close0.5223
Open0.522
Day Range0.522 – 0.591
52-Week Range0.491 – 2.25
Volume216.75K
Market Cap111.05M
P/E (TTM)0.00
Forward P/E10.10
EPS-0.48
Dividend Yield0.00%
Beta3.53
50-Day Avg0.7792
200-Day Avg0.8797

About

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Leonard L. Mazur
  • Employees0
  • Headquarters11 Commerce Drive, Cranford, NJ, United States, 07016, USA
  • Websitehttps://citiusonc.com/overview/default.aspx

Leadership

  • Mr. Leonard L. MazurCEO, President & Executive Chairman · b. 1945
  • Mr. Myron Z. HolubiakSecretary & Executive Vice Chairman · b. 1947
  • Dr. Myron S. Czuczman M.D.Executive VP & Chief Medical Officer · b. 1960
  • Mr. Jaime BartushakCFO & Treasurer · b. 1968

Financials

Income Statement

Currency: USD2021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue-0000
Operating Income--9.71M-12.12M-20.57M-23.52M
EBITDA-10.11K-4.86M-12.12M-20.57M-23.49M
Net Income-10.11K-10.87M-12.70M-21.15M-24.76M
R&D-6.86M4.24M4.92M6.42M
Interest Expense---0218.03K

Balance Sheet

Currency: USD2021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets-42.69M47.73M84.37M100.94M
Total Liabilities-6.42M22.20M38.23M56.08M
Total Equity-36.27M25.54M46.14M44.87M
Cash-289.18K26.52K1123.92M
Total Debt---3.80M3.80M
Net Debt--289.18K-26.52K3.80M-124.80K

Cash Flow

Currency: USD2022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-47.97K-601.30K126.35K-5.49M
Investing Cash Flow-67.32M-1.32M-5.00M-5.75M
Financing Cash Flow67.66M1.66M4.87M15.17M
Capital Expenditure0444
Free Cash Flow-47.97K-601.30K126.35K-5.49M
FCF to OCF100.00%100.00%100.00%100.00%

Earnings

Report DateDec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Aug 28, 2024Dec 30, 2024Feb 17, 2025May 14, 2025Aug 12, 2025Dec 23, 2025Feb 13, 2026May 15, 2026Aug 14, 2026
EPS Estimate--------0.08-0.06-0.09-0.15-0.06-0.02-0.01-0.07
EPS Actual0.040.070.070.020.120.070.04-0.31-0.09-0.11-0.08-0.06-0.06-0.27-0.08
Surprise--------282.38%-55.17%-22.22%46.67%0.00%-200.00%-2600.00%-14.29%
Timing---------After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap111.05M
Enterprise Value100.46M
Trailing P/E0.00
Forward P/E10.10
Price / Sales15.63
Price / Book2.65
EPS-0.48
Book Value0.382
Revenue (TTM)7.11M
Gross Profit (TTM)5.32M
Profit Margin0.00%
Operating Margin-595.55%
Return on Equity-126.58%
Return on Assets-29.12%
Shares Outstanding105.76M
Shares Float30.98M
Beta3.53
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 1 analystsTarget 4.00
  • Hold
    1

Ownership Breakdown

Institutions
15.21%
Insiders
77.51%
Retail / Other
7.28%

Top Institutional Holders

  • Armistice Capital, LLC
    9.19M8.69%
  • Bank of America Corp
    3.84M3.63%
  • Vanguard Capital Management, LLC
    534.82K0.51%
  • Geode Capital Management, LLC
    264.73K0.25%
  • Vanguard Fiduciary Trust Co
    121.91K0.12%
  • IFP Advisors, LLC
    107.42K0.10%
  • Citadel Advisors Llc
    90.59K0.09%
  • BlackRock Inc
    47.45K0.04%
  • Northern Trust Corp
    45.75K0.04%
  • State Street Corp
    42.90K0.04%
  • UBS Group AG
    36.84K0.03%
  • Arkadios Wealth Advisors
    11.67K0.01%
  • Advisor Group Holdings, Inc.
    10.13K0.01%
  • Mercer Global Advisors Inc.
    2000.00%
  • Royal Bank of Canada
    1860.00%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    370.10K0.35%
  • Fidelity Extended Market Index
    98.01K0.09%
  • Fidelity Nasdaq Composite Index
    54.73K0.05%
  • Fidelity Total Market Index
    26.29K0.02%
  • Fidelity Series Total Market Index
    23.39K0.02%